Filing Flows › Ocular Therapeutix (OCUL) › Q3 2026 › vs Q2 2026
Ocular Therapeutix (OCUL) Q3 2026 vs Q2 2026 (quarter over quarter)
Ocular Therapeutix's revenue fell $601K (-4%) from $13.5M in Q2 2026 to $12.9M in Q3 2026.
Ocular Therapeutix, Q3 2026: revenue $12.9M (-12% year over year), operating margin -760.1%, net loss $94.8M, operating cash flow −$65.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $12.9M | $13.5M | −$601K | -4% |
| Other income, net | $3.1M | $3.3M | −$270K | -8% |
| Net loss | $94.8M | $78.8M | $16.0M | +20% |
| Costs & expenses | $111M | $95.6M | $15.1M | +16% |
| Operating costs | $111M | $95.6M | $15.1M | +16% |
| Cost of revenue | $1.5M | $2.0M | −$556K | -28% |
| Research & development | $74.8M | $54.1M | $20.6M | +38% |
| Sales & marketing | $15.7M | $17.3M | −$1.6M | -9% |
| General & admin | $18.8M | $22.2M | −$3.3M | -15% |
| Operating cash sources | $94.8M | $78.8M | $16.0M | +20% |
| Depreciation & amortization | $2.4M | $1.9M | $580K | +31% |
| Share-based compensation | $15.1M | $14.6M | $417K | +3% |
| Working capital & other | $11.7M | −$5.0M | $16.7M | — |
| Cash used in operations | $65.6M | $67.3M | −$1.6M | -2% |
| Net loss absorbed | $94.8M | $78.8M | $16.0M | +20% |
Questions
How much did Ocular Therapeutix's revenue grow quarter over quarter in Q3 2026?
Ocular Therapeutix's revenue fell $601K (-4%) from $13.5M in Q2 2026 to $12.9M in Q3 2026.